1. Acneiform Eruption in a Patient Receiving Bevacizumab for Glioblastoma Multiforme
- Author
-
Bridget P. Keenan and Rachel Abuav
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,genetic structures ,Bevacizumab ,Angiogenesis ,Dermatology ,Acneiform eruption ,Article ,chemistry.chemical_compound ,Internal medicine ,medicine ,Epidermal growth factor receptor ,biology ,business.industry ,General Medicine ,Intravitreal administration ,Diabetic retinopathy ,Macular degeneration ,medicine.disease ,eye diseases ,Vascular endothelial growth factor ,chemistry ,biology.protein ,sense organs ,medicine.symptom ,business ,medicine.drug - Abstract
Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is used in the treatment of several cancers, macular degeneration, and proliferative diabetic retinopathy as a means of limiting angiogenesis, a hallmark feature of these diseases. Nonspecific skin eruption has been reported in some patients receiving bevacizumab, and recently, bevacizumab-associated acneiform eruption was reported in the treatment of colon cancer (systemic administration) and macular degeneration (intravitreal administration).1-3 The eruption in these patients was strikingly similar to that characterized in patients treated with epidermal growth factor receptor (EGFR) inhibitors.1-4 We report a case of bevacizumab-induced acneiform eruption in a patient with glioblastoma multiforme.
- Published
- 2010